Search

Your search keyword '"Matucci‐Cerinic, M."' showing total 2,099 results

Search Constraints

Start Over You searched for: Author "Matucci‐Cerinic, M." Remove constraint Author: "Matucci‐Cerinic, M."
2,099 results on '"Matucci‐Cerinic, M."'

Search Results

3. Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review

5. POS0821 MENOPAUSE AND SYSTEMIC SCLEROSIS: THE LINK BETWEEN MENOPAUSAL AGE, DISEASE ONSET AND CLINICAL MANIFESTATIONS IN AN ANALYSIS OF THE SPRING-SIR REGISTRY

8. AB1183 THE USE OF MYCOPHENOLATE MOFETIL IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS IS ASSOCIATED WITH A REDUCED RISK OF VASCULAR COMPLICATIONS REQUIRING PHARMACOLOGICAL INTERVENTION UPGRADES

9. POS1479-HPR TRAVEL DISTANCE TO TERTIARY HEALTHCARE REFLECTS DISEASE SEVERITY AND MEDICATION ACCESS IN SYSTEMIC SCLEROSIS PATIENTS: INSIGHTS FROM THE ITALIAN SPRING REGISTRY

10. POS0235 NEW ONSET OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: CLINICAL COURSE AND OUTCOMES FROM A EUSTAR DATABASE ANALYSIS

11. POS0211 PAH TREATMENT AT TIME OF DIAGNOSIS IS ASSOCIATED WITH IMPROVED SURVIVAL REGARDLESS OF HEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION - A EUSTAR ANALYSIS

12. POS1099 DIFFICULT-TO-TREAT MANIFESTATIONS OF GRANULOMATOSIS WITH POLYANGIITIS. A EUROPEAN MULTICENTRE STUDY ON SUBGLOTTIC STENOSIS

13. AB1196 BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN SUBJECTS WITH ILD IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS

14. AB1189 THE CIRCULATING LEVELS OF ENDOGENOUS EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC ACID-DERIVED RESOLVINS ARE INCREASED IN SYSTEMIC SCLEROSIS: EVIDENCE FROM A SINGLE CENTRE COHORT

15. POS0832 IMMUNOSUPPRESSION VERSUS COMBINATION OF IMMUNOSUPPRESSION AND ORAL GLUCOCORTICOIDS FOR SKIN FIBROSIS IN EARLY DIFFUSE SYSTEMIC SCLEROSIS PATIENTS. A TARGET TRIAL EMULATION STUDY FROM THE EUSTAR DATABASE

19. POS0842 PRIMARY HEART INVOLVEMENT IN SYSTEMIC SCLEROSIS: THE ROLE OF VENTRICULAR ECTOPIC BEATS AS RED FLAGS FOR ACTIVE MYOCARDIAL INFLAMMATION DETECTED AT CARDIAC MAGNETIC RESONANCE

20. POS0044 DECIPHERING THE GUT MICROBIOTA OF VERY EARLY SYSTEMIC SCLEROSIS (VEDOSS) PATIENTS: A TAXONOMIC AND FUNCTIONAL CHARACTERIZATION

21. OP0265 RITUXIMAB RETENTION RATE IN SYSTEMIC SCLEROSIS: A REAL-LIFE ITALIAN MULTICENTER STUDY

22. OP0225 CHANGES IN TREATMENT PATTERNS AND THEIR INFLUENCE ON THE OUTCOME OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSc-ILD) PATIENTS: AN EUSTAR ANALYSIS

23. POS0826 PREDICTORS OF RESPONSE AND LONG-TERM EFFICACY AND SAFETY OF NINTEDANIB IN SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE: DATA FROM AN ITALIAN MULTICENTRE STUDY

25. OP0073 UNRAVELING PATHOPHYSIOLOGY AND HEMATOPOIESIS OF VEXAS SYNDROME BY MULTI-OMICS ANALYSIS AND TARGETED GENE EDITING

26. POS0843 IMMUNOSUPPRESSIVE THERAPY TO TREAT NEWLY DIAGNOSED PRIMARY HEART INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: AN ITALIAN CARDIAC MAGNETIC RESONANCE BASED STUDY

30. POS0432 DRIVERS OF DISEASE BURDEN IN PATIENTS WITH SYSTEMIC SCLEROSIS ACROSS CLINICAL AND DEMOGRAPHIC SUBGROUPS REVEALED BY THE EULAR SYSTEMIC SCLEROSIS IMPACT OF DISEASE (ScleroID) QUESTIONNAIRE

31. The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis

32. Systematic Literature Review and Expert Opinion for the Use of Viscosupplementation with Hyaluronic Acid in Different Localizations of Osteoarthritis

33. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology

37. POS0613 THE ROLE OF MICROBIOTA IN DIFFERENT DISEASE STAGES OF SYSTEMIC SCLEROSIS: A POSSIBLE IMPACT IN GASTROINTESTINAL TRACT DISEASE ACTIVITY?

39. AB0771 FEMALE GENDER AND STEROID TREATMENT AS MAIN INFLUENCING FACTORS IN THE PERCEPTION OF QUALITY OF LIFE IN ANCA-ASSOCIATED VASCULITIS: FINAL RESULTS FROM THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE

41. POS1275 THE HETEROGENEITY OF DEFINING SEVERITY, PROGRESSION AND OUTCOMES IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW

43. OP0238 IMMUNOSUPPRESSION WITH TARGETED DMARDS REDUCES MORBIDITY AND MORTALITY IN PRE-CAPILLARY PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: A EUSTAR ANALYSIS

44. POS1313 EFFICACY OF IMMUNOGLOBULIN TREATMENT ON GASTROINTESTINAL, CUTANEOUS AND VASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS: DATA FROM AN ITALIAN COHORT OF 65 PATIENTS

45. OP0234 2023 UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS

46. POS1263 SMOKING INFLUENCE ON AUTOANTIBODY PROFILE AND DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: AN EUSTAR DATABASE ANALYSIS

47. POS1278 SAFETY AND PHARMACOKINETICS OF IGPRO20 (SUBCUTANEOUS IMMUNOGLOBULIN) AND IGPRO10 (INTRAVENOUS IMMUNOGLOBULIN) IN ADULTS WITH SYSTEMIC SCLEROSIS (SSC) – RESULTS FROM A PHASE 2 TRIAL

48. POS0121 COMPARISON OF FOUR RISK STRATIFICATION MODELS FOR PREDICTION OF MORTALITY IN SSc-PAH IN THE EUSTAR COHORT

49. POS1587-HPR DISABILITY IN AN ITALIAN COHORT OF RHEUMATIC DISEASES: A MIXED METHOD STUDY FOR THE ANALYSIS OF THE PHENOMENON AND PROPOSALS FOR NURSING APPROACH

Catalog

Books, media, physical & digital resources